TL:DR 50% reduction in AHI (apnea-hypoxia index) and a lowering of blood pressure (which may reduce risk of stroke and heart attack!)
Obstructive sleep apnea is one of the most common respiratory disorders worldwide. Persons with obstructive sleep apnea can have loud snoring that is detrimental to social relationships and have breathing problems that result in recurrent nocturnal awakenings, unrefreshing sleep, and excessive daytime sleepiness — effects that together can substantially impair quality of life.

The improvement in systolic blood pressure that was seen with tirzepatide was substantially larger than effects seen with CPAP therapy alone7 and indicate that tirzepatide may be an attractive option for those patients who seek to reduce their cardiovascular risk
The initial results from the SURMOUNT-OSA trial show the usefulness of tirzepatide as an adjunctive treatment to address coexisting obesity in patients with obstructive sleep apnea. Weight loss resulting from tirzepatide treatment may be leveraged to expand the populations that may benefit from second-line treatments for obstructive sleep apnea.




